What is HC Wainwright's Forecast for WVE FY2026 Earnings?

Key Points

• HC Wainwright projects WAVE Life Sciences will lose $1.09 per share in FY2026, slightly better than the consensus estimate of a $1.11 loss, and rates the stock “Strong Buy.”
• The firm expects losses to continue but narrow over time, from $1.09 per share in FY2027 to $0.47 per share by FY2030.
• WAVE recently exceeded third-quarter expectations, reporting a $0.30 per-share loss versus the projected $0.33 loss and revenue of $13.16 million compared with the $4.51 million consensus estimate.

WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for WAVE Life Sciences in a research report issued on Wednesday, October 28th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($1.09) per share for the year. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for WAVE Life Sciences' current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for WAVE Life Sciences' Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.28) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.47) EPS.

A number of other equities analysts have also commented on WVE. Wall Street Zen lowered WAVE Life Sciences from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 1st. Leerink Partners set a $10.00 price objective on shares of WAVE Life Sciences in a research report on Tuesday. JPMorgan Chase & Co. initiated coverage on WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a "neutral" rating for the company. Wedbush set a $13.00 price target on shares of WAVE Life Sciences in a research note on Friday, October 2nd. Finally, Zacks Research cut WAVE Life Sciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.89.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $3.63 on Friday. The stock's 50 day simple moving average is $4.10 and its 200 day simple moving average is $7.55. WAVE Life Sciences has a one year low of $3.04 and a one year high of $21.73. The firm has a market cap of $715.94 million, a PE ratio of -3.39 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%.

Insider Transactions at WAVE Life Sciences

In other news, Director Heidi L. Wagner sold 7,000 shares of the company's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the sale, the director owned 44,930 shares in the company, valued at $270,029.30. This represents a 13.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 23,564 shares of company stock valued at $132,476. Company insiders own 24.34% of the company's stock.

Institutional Investors Weigh In On WAVE Life Sciences

Several hedge funds have recently bought and sold shares of the company. Readystate Asset Management LP bought a new position in shares of WAVE Life Sciences in the second quarter valued at about $27,465,000. Squarepoint Ops LLC raised its holdings in WAVE Life Sciences by 68.0% in the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company's stock valued at $14,766,000 after acquiring an additional 1,029,052 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in WAVE Life Sciences by 42.6% during the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company's stock worth $8,202,000 after buying an additional 343,226 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company's stock worth $4,330,000 after acquiring an additional 360,800 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of WAVE Life Sciences by 12.4% during the 1st quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company's stock worth $2,619,000 after buying an additional 39,759 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Third-quarter results beat expectations: WAVE reported $13.16 million in revenue versus the $4.51 million consensus estimate and a loss of $0.30 per share, narrower than the expected $0.33 loss. The results helped reduce near-term concerns about the company’s financial performance. Wave Life Sciences Stock Rallies As Q3 Results Ease Loss Fears
• Positive Sentiment: HC Wainwright initiated coverage with a Strong-Buy rating: The firm’s forecasts call for losses of $1.09 per share in fiscal 2026 and fiscal 2027, narrowing to $0.79 in 2028, $0.68 in 2029 and $0.47 in 2030. The rating indicates confidence in WAVE’s longer-term potential despite continued projected losses. HC Wainwright WAVE Coverage
• Positive Sentiment: Additional bullish attention supported the rally: Reports highlighted WAVE among healthcare stocks viewed favorably by analysts, while separate coverage noted that the shares rose after the strong earnings release. Analysts Are Bullish on WAVE
• Neutral Sentiment: Oppenheimer remained constructive but reduced its price target: The firm lowered its target to $29 from $32 while maintaining an Outperform rating, creating a mixed signal for investors. Oppenheimer Adjusts WAVE Price Target
• Negative Sentiment: Profitability remains a significant risk: HC Wainwright expects WAVE to continue posting quarterly and annual losses through 2030. The company’s negative net margin and ongoing cash needs could limit the durability of the earnings-driven advance.

About WAVE Life Sciences

WAVE Life Sciences Ltd. NASDAQ: WVE is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.